Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 5,132 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: AIDS (Acquired Immunodeficiency Syndrome) Clear all
Completed Phase 2 Interventional

Behavior Change and Maintenance Intervention for HIV+ MSM Methamphetamine Users

NCT00432926
View directory record Official record
Conditions
HIV Infections, Substance Abuse, Sexually Transmitted Diseases
Interventions
EDGE counseling, no maintenance, EDGE counseling, plus maintenance, Attention control
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 22, 2026, 5:20 AM EDT
Active, not recruiting Not applicable Interventional

ResIlience-based Stigma REdUction Program ("Rise-up")

NCT05174936
View directory record Official record
Conditions
HIV/AIDS, Stigma, Social, Emotional Adjustment
Interventions
PLWH intervention, Family member intervention, Healthcare provider intervention
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
1,928 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)

NCT03251144
View directory record Official record
Conditions
HIV/AIDS, Antiviral Toxicity, Antiviral Drug Adverse Reaction, Mitochondrial Alteration
Interventions
Switch to E/C/FTC/TAF daily
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants

NCT06310616
View directory record Official record
Conditions
HIV Infections
Interventions
VH4524184, Loestrin
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults

NCT00301184
View directory record Official record
Conditions
HIV Infections
Interventions
pGA2/JS7 DNA, Modified vaccinia Ankara/HIV62
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
6
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 2 Interventional

A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug Treatment

NCT00006152
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Abacavir sulfate, Amprenavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir

NCT03234036
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK2838232 100 mg tablet, GSK2838232 50 mg capsule, Ritonavir 100 mg tablets, Placebo for GSK2838232 tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 3 Interventional

The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine

NCT00002371
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1997
U.S. locations
5
States / cities
Torrance, California • Tampa, Florida • Stony Brook, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 4, 2011 · Synced Oct 22, 2026, 5:20 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

NC Young Women's CoOp

NCT02965014
View directory record Official record
Conditions
Condomless Sex, Human Immunodeficiency Virus (HIV), Sexually Transmitted Infection (STI), Alcohol and Drug Use
Interventions
Face-to-Face Young Women's CoOp (YWC), mHealth Young Women's CoOp (YWC), HIV Counseling and Testing
Behavioral
Lead sponsor
RTI International
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
652 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
4
States / cities
Durham, North Carolina • Greensboro, North Carolina • High Point, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women

NCT01505114
View directory record Official record
Conditions
HIV Infection
Interventions
Maraviroc, Emtricitabine, Tenofovir disoproxil fumarate, Maraviroc placebo, Emtricitabine placebo, Tenofovir disoproxil fumarate placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 2 Interventional

Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma

NCT00006264
View directory record Official record
Conditions
Lymphoma
Interventions
aldesleukin, ganciclovir, zidovudine
Biological · Drug
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
2
States / cities
Miami, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 22, 2026, 5:20 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.

NCT04840199
View directory record Official record
Conditions
HIV Infections, Cytomegalovirus, CMV
Interventions
Letermovir Oral Tablet
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
40 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 22, 2026, 5:20 AM EDT
Recruiting Phase 2 Interventional

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

NCT02479698
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, BK Virus Infection, Human Immunodeficiency Virus, JC Virus Infection, Malignant Neoplasm, Merkel Cell Carcinoma, Merkel Cell Polyomavirus Infection, Viral Encephalitis
Interventions
Allogeneic BK-specific Cytotoxic T-lymphocytes, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy

NCT00870363
View directory record Official record
Conditions
HIV Infections
Interventions
maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor), maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor), efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Not applicable Interventional

A Simple Intervention to Increase Persistence on PrEP in MSM to Improve Decision Making

NCT06476847
View directory record Official record
Conditions
HIV Infections
Interventions
PrEP persistence
Behavioral
Lead sponsor
Boston University
Other
Eligibility
18 Years and older · Male only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 22, 2026, 5:20 AM EDT
Terminated Not applicable Interventional

Implementing Cabenuva in Arkansas HIV Programs

NCT05096949
View directory record Official record
Conditions
HIV-1-infection, Medication Adherence, Satisfaction, Patient
Interventions
Home visit delivery strategy
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Not applicable Interventional Results available

HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 1

NCT05560932
View directory record Official record
Conditions
HIV, Alcohol Use
Interventions
IMB-motivational interviewing (MI) techniques (IMB-MI)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 2 Interventional

Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting

NCT00642499
View directory record Official record
Conditions
Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting, HIV Infections
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
36
States / cities
Bakersfield, California • Fresno, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2008 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Not applicable Interventional

Intervention to Assist MSM Disclose HIV Status to Casual Sex Partners

NCT02116049
View directory record Official record
Conditions
HIV
Interventions
Disclosure Intervention, Attention Control Case Management
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older · Male only
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV

NCT00084149
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine, and Zidovudine, Lopinavir/Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
4
States / cities
Minneapolis, Minnesota • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants

NCT04857892
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254, DTG, GSK3640254/DTG
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 22, 2026, 5:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessing the Engagement of Transgender and Other Gender Minority Youth Across the HIV Continuum of Care

NCT02449629
View directory record Official record
Conditions
Transgender, HIV Continuum of Care
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 24 Years
Enrollment
187 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
14
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Not applicable Interventional

Translating the ABCS Into HIV Care

NCT03902431
View directory record Official record
Conditions
HIV, Cardiovascular Risk Factor
Interventions
ABCS training
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
40 Years to 79 Years
Enrollment
4,277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

HIV Testing & Womens Attitudes on HIV Vaccine Trials

NCT00771537
View directory record Official record
Conditions
HIV
Interventions
Message Sidedness
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
2,031 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Oct 22, 2026, 5:20 AM EDT